

BUDGET FACT BOOK

FOR FISCAL YEAR 2023



TABLE OF CONTENTS

3 NCI BUDGET FACT BOOK

- 3 Fiscal Year 2023 Highlights
- 4 Where to Find Information from Previous Fact Books

6 NCI BUDGET SUMMARY DATA

- 6 Most Recent Reported Fiscal Year Budget
- 7 Funding Allocated to Major NCI Program Areas
- 8 Extramural Funding
- 10 Obligations by Budget Mechanism and Division
- 28 NIH Management Fund, Service and Supply Fund (SSF), and GSA Rent
- 31 Special Sources of Funds
- 36 Funding for Research Areas

39 NCI EXTRAMURAL PROGRAMS

- 39 Research Project Grants (RPGs)
- 49 Grants to NCI-Designated Cancer Centers
- 56 Specialized Programs of Research Excellence (SPOREs)
- 59 Dr. Ruth L. Kirschstein National Research Service Awards (NRSA)
- 60 Research Career Awards “K” Program
- 62 Grant and Contract Awards

68 NCI HISTORICAL TRENDS

- 68 NCI Professional Judgment Budget, President’s Budget and Appropriations
- 77 NCI Funding Trends
- 80 Extramural vs Intramural and RMS Funding
- 84 Comparison of Dollars, Positions, and Space
- 85 NCI Personnel
- 86 NCI and NIH AIDS Funding History

87 CANCER MOONSHOTSM – RECENT FISCAL YEAR FUNDING

- 88 Cancer MoonshotSM - Obligations by Budget Mechanism
- 91 Cancer MoonshotSM - Funding by Research Category

NCI Budget Fact Book

This report provides a summary of the distribution of the fiscal year 2023 budget among the various NCI research programs and funding mechanisms, funding policies influencing grant awards, and comparisons with prior year allocations.

Fiscal Year 2023 Highlights

Funds available to NCI totaled \$7.1 billion, post inter-departmental and intra-NIH transfers, including \$50 million for the Childhood Cancer Data Initiative and \$28 million for Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act. This reflects an increase of 5.7% and \$385.6 million from the previous fiscal year.

Fiscal year highlights include:

- The Childhood Cancer Data Initiative (CCDI) will facilitate a connected data infrastructure and integrate multiple data sources to make data work better for patients, clinicians, and researchers.
- The Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act, which was signed into law in June 2018, authorized funds for NCI to expand existing biorepositories for childhood cancer patients enrolled in NCI-sponsored clinical trials to collect and maintain relevant clinical, biological, and demographic information on children, adolescents, and young adults, and to continue to conduct and support pediatric cancer survivorship research.
- The 21st Century Cures Act, which was signed into law in December 2016, authorized \$1.8 billion to fund the Cancer Moonshot over a 7-year period. The Cancer Moonshot funding received during fiscal year 2023 totaled \$216 million.
- Of the total NCI budget obligated, 43.8% of the funds were allocated for Research Project Grants (RPGs).
- The total number of RPGs funded was 5,736, including grants funded through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.
- One-fourth of the RPGs awarded were new ("Type 1") or competing renewal ("Type 2") awards.
- There was a total of 1,369 competing RPGs funded, excluding grants funded through SBIR and STTR.
- One-third of the total NCI budget supported ongoing, non-competing ("Type 5") RPGs.
- The R01 grants were funded to the 12th percentile for Experienced and New Investigators and the Early-Stage Investigators were funded to the 17th percentile.
- R01 Early-Stage Investigators between the 1st and 12th percentiles were converted to R37 awards giving them the opportunity to extend their research an additional 2 years.

- SBIR and STTR awards funded 228 grants totaling \$175.4 million.
- Intramural research comprised 18% of the total NCI budget.


The dollar amounts displayed in the NCI Budget Fact Book represent direct appropriated funds only, unless otherwise denoted.

Where to Find Information from Previous Fact Books

Information provided in previous Fact Books can now be found online. For example, view NCI's Organization Chart on the NIH Office of Management Assessment website. Cancer statistics can be found on the NCI website, as well as more detailed NCI Organization information. A limited number of Fact Books from prior years are available as hardcopy publications through the NCI Publications Locator. Find PDFs of all the NCI Budget Fact Books, dating back to 1971.

The NCI Budget Fact Book data is organized into the following sections. If you have any questions, please contact the Office of Budget and Finance (OBF).

Budget At A Glance: Fiscal Year 2023



NCI BUDGET
INCREASED BY
\$385.6 MILLION
(5.7%) FROM
FISCAL YEAR 2022

43.8%


OF THE TOTAL
NCI BUDGET
ALLOCATED FOR
RESEARCH
PROJECT GRANTS

THE NATIONAL CANCER INSTITUTE (NCI) PROVIDES FUNDING AND SUPPORT FOR HEALTH-RELATED RESEARCH AND DEVELOPMENT THROUGH THE RPG (R01) GRANT MECHANISM.




R01 GRANTS
FUNDED TO THE

12TH
PERCENTILE



OF RPG
AWARDS WERE
NEW (TYPE 1)
OR COMPETING
RENEWAL (TYPE
2) AWARDS



OF THE TOTAL
NCI BUDGET
SUPPORTED
ONGOING,
NON-COMPETING
(TYPE 5) RPGs

1,369
NCI-FUNDED
COMPETING RPGs



TOTALING OVER \$175.4 MILLION
FUNDED AS SMALL BUSINESS
INNOVATION RESEARCH (SBIR) AND
SMALL BUSINESS TECHNOLOGY
TRANSFER (STTR) AWARDS.

5,736

TOTAL
NCI-FUNDED RPGs
(INCLUDING SBIR)

NCI Budget Summary Data

This section of the NCI Budget Fact Book provides data about funds available to NCI and information on how NCI obligated its funding.

Most Recent Reported Fiscal Year Budget

In fiscal year 2023, Congress passed a consolidated appropriations act allocating \$7.104 billion to NCI. NCI was also appropriated \$216 million in fiscal year 2023 as a result of the 21st Century Cures Act. After permissive transfers, \$7.231 billion was available to NCI to obligate.

In addition to the appropriated amount for the fiscal year, NCI entered into inter- and intra-agency agreements with other federal agencies and NIH Institutes and Centers (ICs). These agreements often provide reimbursements for materials, supplies, equipment, work, or services to assist other agencies and ICs accomplish their missions.

FISCAL YEAR 2023 BUDGET

(Whole Dollars)

Actual Obligations Resulting From Appropriated Funds	FY 2023 Amount
FY 2023 Appropriation	\$7,104,159,000
FY23 Cancer Moonshot Appropriation	\$216,000,000
Secretary's Transfer	\$0
Transfer to NIH Office of AIDS Research	-\$2,918,000
Lapse	-\$234,418
Cancer Moonshot Carryover	-\$129,405,086
Actual Obligations Subtotal	\$7,187,601,496
Reimbursable Obligations	\$43,693,202
Total NCI Obligations	\$7,231,294,698


Includes FY23 Cures MoonshotSM funding and excludes fiscal years 2022 through 2017 Cures Moonshot carryover obligations.

Funding Allocated to Major NCI Program Areas

Each fiscal year, NCI and other NIH Institutes and Centers report their obligations by mechanism. In addition to reporting by mechanism, reporting obligations by program structure is another way of showing how NCI obligates its funding each fiscal year.

For the purposes of reporting by program structure, NCI programs are categorized by budget activity. These budget activities include:

- **Research**, categorized by the following research thrusts: Childhood Cancer Data Initiative (CCDI), cancer causation, detection and diagnosis, treatment, and cancer biology
- **Resource Development**: cancer centers, research manpower development, and buildings and facilities
- **Cancer Prevention and Control**
- **Program Management and Support**



cancer.gov


*Includes fiscal year 2023 Cures MoonshotSM funding and excludes fiscal years 2022 through 2017 Cures Moonshot carryover obligations. Total CCDI costs is \$50 million when including the CCDI cancer centers obligations.

Extramural Funding

Overall, NCI obligations for its extramural program, which includes grants and contracts, totaled \$5.41 billion in fiscal year 2023.

- Obligations for grants totaled approximately 82.8% of extramural funding
- Obligations for contracts totaled approximately 17.2% of extramural funding

Obligations on this page include fiscal year 2023 Cancer MoonshotSM funding and excludes fiscal years 2022 through 2017 Cures Moonshot carryover obligations.



EXTRAMURAL FUNDS, FISCAL YEAR 2023

(Whole Dollars)

Mechanism	Amount	Percent
Research & Development (R&D) Contracts	\$899,070,171	16.6%
Buildings and Facilities	\$30,000,000	0.6%
Construction Contracts	0	0.0%
Subtotal Contracts	\$929,070,171	17.2%
Research Project Grants (RPGs)	\$3,145,236,780	58.1%
Cancer Centers/Specialized Centers/SPORES	\$624,438,597	11.5%
NRSA	\$90,324,558	1.7%
Other Research Grants	\$621,500,774	11.5%
Subtotal Grants	\$4,481,500,709	82.8%
Total Extramural Funds	\$5,410,570,880	100.0%
<i>Intramural/RMS Funds</i>		\$1,776,330,616
Total NCI		\$7,186,901,496


Obligations by Budget Mechanism and Division

All NIH Institutes and Centers report their actual obligations each fiscal year by budget mechanism. The tables below display NCI funding by mechanism and division. The number of awards, trainees, or employees for each mechanism, as well as the dollar amount and percent share of the total NCI budget for each funding mechanism is also included.

NCI Obligations by Mechanism

Percent Share of Total NCI Dollars

Fiscal Year 2023



cancer.gov

Other research mechanisms includes the following grants: Career Programs (K Awards), Cancer Education, Clinical Cooperative Groups, Pre-Doc Post-Doc Transition Awards, Education Projects - Cooperative Agreements, Minority Biomedical Research Support, Research Pathway in Residency, Pilot Research Project, Resource Grants, International Research Training grants, Cooperative Conference Agreements, Conference grants, and Other Transaction Authority (OTA).

NCI OBLIGATIONS BY MECHANISM, FY 2023

(Whole Dollars)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Research Project Grants (RPGs)	Non-Competing	4,139	\$2,232,418,863	31.1%
	Administrative Supplements	354	\$39,659,222	0.6%
	Competing	1,369	\$697,785,647	9.7%
	Subtotal, without SBIR/STTR Grants	5,508	\$2,969,863,732	41.3%
	SBIR/STTR Grants	228	\$175,373,048	2.4%
	Subtotal, RPGs	5,736	\$3,145,236,780	43.8%
Centers & SPOREs	Cancer Centers Grants-P20/P30	82	\$353,500,692	4.9%
	SPOREs	63	\$124,109,217	1.7%
	Other P50s/P20s	4	\$5,302,188	0.1%
	Other Specialized Centers	100	\$141,526,500	2.0%
	Subtotal, Centers	249	\$624,438,597	8.7%
Other Research	Career Program			0.0%
	Post-Doc-Fellow Awards-K00	81	\$7,511,395	0.1%
	Research Scientist Development Award-K01	30	\$4,930,862	0.1%

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Other Research	Academic/Teacher Award-K07	1	\$636,196	0.0%
	Clinical Investigator Award-K08	262	\$60,838,215	0.8%
	Physician Scientist Award (Program)-K12	23	\$14,203,536	0.2%
	Transitional Career Development-K22	60	\$11,108,024	0.2%
	Mentored Quant. Res Career-K25	2	\$377,331	0.0%
	International Research Career Development Award-K43	1	\$416,344	0.0%
	Career Transition Award-K99	76	\$10,313,551	0.1%
	Subtotal, Career Program	536	\$110,335,454	1.5%
	Cancer Education Program-R25 (including BD2K)	83	\$23,218,691	0.3%
	Clinical Cooperative Groups-U10/UG1	118	\$303,623,771	4.2%
	PreDoc PostDoc Transition Awards-F99	0	\$1,955,422	0.0%
	Education Projects-UE5	0	\$528,237	0.0%
	Minority Biomedical Support-S06	0	\$2,563,376	0.0%

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Other Research	Research Pathway in Residency-R38	0	\$1,233,360	0.0%
	Other Transaction Authority-OT2	0	\$19,684,436	0.3%
	Resource Grants-R24/U24/U2C	12	\$154,268,060	2.1%
	Cooperative Conference Agreements-U13/R13	0	\$1,050,263	0.0%
	International Research Training Grants Conference-D43	0	\$3,039,704	0.0%
	International Training Cooperative Agreement-U2R	0	\$0	0.0%
	Subtotal, Career and Other Research Grants	749	\$621,500,774	8.6%
Subtotal, Research Grants		6,734	\$4,391,876,151	61.1%
National Research Service Award (NRSA) Fellowships	<i>Trainees</i>	1,559	\$90,324,558	1.3%

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
R&D Contracts	R&D Contracts	409	\$738,215,732	10.3%
	SBIR Contracts	29	\$24,397,507	0.3%
	NIH Management Fund/SSF Assessment	0	\$136,456,932	1.9%
	Subtotal, Contracts	438	\$899,070,171	12.5%
Intramural Research	Program	1,865	\$983,006,934	13.7%
	NIH Management Fund/SSF Assessment	0	\$295,537,156	4.1%
	Subtotal, Intramural Research (FTEs)	1,865	\$1,278,544,090	17.8%
Research Management & Support (RMS)	Research Management and Support (RMS)	1,385	\$384,080,402	5.3%
	SBIR RMS	0	\$3,483,639	0.0%
	NIH Management Fund/SSF Assessment	0	\$110,222,485	1.5%
	Subtotal, RMS (FTEs)	1,385	\$497,786,526	6.9%
Buildings & Facilities		0	\$30,000,000	0.4%
*Total NCI	(FTEs)	3,250	\$7,187,601,496	100%

All items in italics are non-add entries.

*Includes FY23 Cures-Moonshot funding.

*Excludes FY22 through FY17 Cures-Moonshot carryover obligations.

Division Obligations by Mechanism

DIVISION OBLIGATIONS

Total Division Obligations, FY 2023

(Whole Dollars)

Division	Total
Center for Cancer Research (CCR)	\$598,072,228
Division of Cancer Epidemiology and Genetics (DCEG)	\$115,754,029
Division of Cancer Treatment and Diagnosis (DCTD)	\$595,710,724
Division of Cancer Biology (DCB)	\$59,954,941
Division of Cancer Control and Population Sciences (DCCPS)	\$153,317,190
Division of Cancer Prevention (DCP)	\$238,130,638
Division of Extramural Activities (DEA)	\$21,813,439
Office of the Director (OD)	\$1,724,988,746
Total Division	\$6,535,805,879

CENTER FOR CANCER RESEARCH (CCR)

CCR Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Intramural Research	Program	\$598,072,228
	NIH Management Fund	0
Total CCR		\$598,072,228

DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS (DCEG)

DCEG Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
R&D Contracts	R&D Contracts	\$15,304,016
	SBIR Contracts	0
	Subtotal, Contracts	\$15,304,016
Intramural Research	Program	\$100,450,013
	NIH Management Fund	0
	Subtotal, Contracts	\$100,450,013
Total DCEG		\$115,754,029

DIVISION OF CANCER TREATMENT AND DIAGNOSIS (DCTD)

DCTD Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	\$0
	SPOREs-P50	\$117,621,136
	Other P50s/P20s	\$0
	Other Specialized Centers	\$18,086,776
	Subtotal, Centers	\$135,707,912

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Other Research–Grants	Cancer Education Program-R25 (including BD2K)	\$0
	Education Projects-UE5	\$0
	Clinical Cooperative Groups-U10/UG1	\$143,878,408
	PreDoc PostDoc Transition Awards-F99	\$0
	Minority Biomedical Support-S06	\$0
	Rsrch Pathway in Residency-R38	\$0
	Pilot Research Project-OT2	\$0
	Resource Grants-R24/U24/U2C	\$0
	Cooperative Conference Agreements-U13/R13	\$0
	International Research Training Grant-D43	\$0
	International Training Cooperative Agreement-U2R	\$0
	Subtotal, Other Research- Grants	\$143,878,408
Subtotal, Research Grants		\$279,586,320

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
R&D Contracts	R&D Contracts	\$248,976,185
	SBIR Contracts	\$0
	NIH Management Fund/SSF Assessment	\$0
	Subtotal, Contracts	\$248,976,185
Research Management & Support (RMS)	RMS	\$67,148,219
	SBIR RMS	\$0
	NIH Management Fund/SSF Assessment	\$0
	Subtotal, RMS	\$67,148,219
Total DCTD		\$595,710,724

DIVISION OF CANCER BIOLOGY (DCB)

DCB Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	\$0
	SPOREs-P50	0
	Other P50s/P20s	\$587,068
	Other Specialized Centers	\$44,316,999
	Subtotal, Centers	\$44,904,067
Other Research-Grants	Subtotal, Other Research-Grants	\$0
Subtotal, Research Grants		\$44,904,067
R&D Contracts	R&D Contracts	\$66,552
	SBIR Contracts	0
	NIH Management Fund/SSF Assessment	0
	Subtotal, Contracts	\$66,552
Research Management & Support (RMS)	RMS	\$14,984,322
	SBIR RMS	0
	NIH Management Fund	0
	Subtotal, RMS	\$14,984,322
Total DCB		\$59,954,941

DIVISION OF CANCER CONTROL AND POPULATION SCIENCES (DCCPS)

DCCPS Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	\$0
	SPOREs-P50	0
	Other P50s/P20s	\$5,302,188
	Other Specialized Centers	\$10,120,819
	Subtotal, Centers	\$15,423,007
Other Research	Cancer Education Program-R25 (including BD2K)	\$0
	Education Projects-UE	\$0
	Clinical Cooperative Groups-U10/UG1	\$0
	PreDoc PostDoc Transition Awards-F99	\$0
	Education Projects-UE5	\$0
	Minority Biomedical Support-S06	\$0
	Research Pathway in Residency-R38	\$0
	Pilot Research Project-OT2	\$0
	Resource Grants-R24/U24/U2C	\$0
	Cooperative Conference Agreements-U13/R13	\$0

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Other Research	Int'l Research Training Grants-D43/U2R	\$0
	International Training Cooperative Agreement-U2R	\$0
	Subtotal, Other Research Grants	\$0
Subtotal, Research Grants		\$15,423,007
R&D Contracts	R&D Contracts	\$95,860,843
	SBIR Contracts	\$0
	NIH Management Fund/SSF Assessment	\$0
	Subtotal, Contracts	\$95,860,843
Research Management & Support (RMS)	RMS	\$42,033,340
	SBIR RMS	0
	NIH Management Fund	0
	Subtotal, RMS	\$42,033,340
Total DCCPS		\$153,317,190

DIVISION OF CANCER PREVENTION (DCP)

DCP Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	\$0
	SPOREs-P50	0
	Other P50s/P20s	0
	Other Specialized Centers	\$10,110,005
	Subtotal, Centers	\$10,110,005
Other Research–Grants	Cancer Education Program-R25 (including BD2K)	\$0
	UE5 Education Projects	\$0
	Clinical Cooperative Groups-U10/UG1	\$153,267,629
	PreDoc PostDoc Transition Awards-F99	\$0
	Minority Biomedical Support-S06	\$0
	Rsrch pathway in Residency-R38	\$0
	Pilot Research Project-OT2	\$0
	Resource Grants-R24/U24/U2C	\$0
	Cooperative Conference Agreements-U13/R13	\$0

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Other Research–Grants	International Research Training Grants-D43	\$0
	International Training Cooperative Agreement-U2R	\$0
	Subtotal, Other Research Grants	\$153,267,629
Subtotal, Research Grants		\$163,377,634
R&D Contracts	R&D Contracts	\$45,967,374
	SBIR Contracts	\$0
	NIH Management Fund/SSF Assessment	\$0
	Subtotal, Contracts	\$45,967,374
Research Management & Support (RMS)	RMS	\$28,785,630
	SBIR RMS	0
	NIH Management Fund/SSF Assessment	0
	Subtotal, RMS	\$28,785,630
Total DCP		\$238,130,638

DIVISION OF EXTRAMURAL ACTIVITIES (DEA)

DEA Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Research Management & Support (RMS)	RMS	\$21,813,439
	SBIR RMS	0
	NIH Management Fund	0
Total DEA		\$21,813,439

OFFICE OF THE DIRECTOR (OD)

OD Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
Research Project Grants (RPGs)	Noncompeting	\$0
	Administrative Supplements	\$0
	Competing	\$0
	Subtotal, without SBIR/STTR Grants	\$0
	SBIR/STTR Grants-R41 -44	\$175,373,048
	Subtotal, RPGs	\$175,373,048

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/P30	\$352,913,624
	SPOREs	\$4,348,587
	Other P50s/P20s	\$0
	Other Specialized Centers	\$60,668,325
	Subtotal, Centers	\$417,930,536
Other Research–Career Program	Career Program	\$0
	Post-Doc-Fellow Awards-K00	\$7,511,395
	Research Scientist Development Award-K01	\$4,930,862
	Research Scientist Award-K05	\$0
	Academic/Teacher Award-K07	\$636,196
	Clinical Investigator-K08	\$60,838,215
	Physician Scientist Award (Program)-K12	\$14,203,536
	Transitional Career Development-K22	\$11,108,024
	Mentored Patient Oriented RCDA-K23	\$0
	Mid-Career Invest. & Patient Orient. Res-K24	\$0
	Mentored Quant. Res Career-K25	\$377,331
	International Research Career Development Award-K43	\$416,344

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
Other Research–Career Program	Career Transition Award-K99	\$10,313,551
	Subtotal, Career Program	\$110,335,454
Other Research–Grants	Cancer Education Program-R25 (including BD2K)	\$23,218,691
	Education Projects-UE5	\$0
	Clinical Cooperative Groups-U10/UG1	\$6,477,734
	PreDoc PostDoc Transition Awards-F99	\$0
	Minority Biomedical Support-S06	\$0
	Rsrch Pathway in Residency-R38	\$0
	Pilot Research Project-OT2	\$0
	Resource Grants-R24/U24/U2C	\$19,496,381
	Cooperative Conference Agreements-U13/R13	\$0
	International Research Training Grants-D43	\$0
	International Training Cooperative Agreement-U2R	\$0
	Subtotal, Other Research–Grants	\$49,192,806
Subtotal, Research Grants		\$752,831,844

(Continued from previous page)

Type of Mechanism	Mechanism	Amount
NRSA Fellowships		\$88,434,849
	R&D Contracts	\$332,040,762
	SBIR Contracts	\$24,397,507
	NIH Management Fund/ SSF Assessment/Program Evaluation	\$0
	Subtotal, Contracts	\$356,438,269
Intramural Research	Program	\$284,484,693
	NIH Management Fund/ SSF Assessment/Program Evaluation	0
	Subtotal, Intramural Research	\$284,484,693
Research Management & Support (RMS)	RMS	\$209,315,452
	SBIR RMS	\$3,483,639
	NIH Management Fund/ SSF Assessment/Program Evaluation	\$0
	Subtotal, RMS	\$212,799,091
Buildings and Facilities		\$30,000,000
Total OD		\$1,724,988,746

NIH Management Fund, Service and Supply Fund (SSF), and GSA Rent

The NIH Management Fund provides for the financing of certain common research and administrative support activities, which are required in the operations of NIH:

Clinical Center: Admissions and follow-up, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition services, housekeeping services, laundry, social work, drug costs, red team response, bench to bedside, and the Children's Hospital.

Center for Scientific Review: Initial scientific review of applications and assignment of research grant applications to institutes.


Center for Information Technology: Research and development program in which concepts and methods of computer science are applied to biomedical problems.

Other Research Services: Procurement, safety, engineering, biomedical engineering, veterinary resources, and library services have moved to Service and Supply fund.

Service & Supply Fund: Mainframe computing, enterprise IT software planning and development, engineering planning and design, printing, telecommunications, procurement, shipping and receiving, motor pool, research animals, fabrication and maintenance of scientific equipment, utilities and plant maintenance, biomedical engineering, background investigations, IT cybersecurity, and General Services Administration (GSA) rental payments for space (to include all building rental costs, utilities and guard services) and Other Research Services (to include procurement, safety, engineering and biomedical engineering).

NIH Management Fund, Service & Supply Fund, and GSA Rent

Fiscal Year 2023



cancer.gov

NCI FISCAL YEAR 2023 MANAGEMENT FUND, SSF, AND GSA RENT

(Whole Dollars)

Distribution of NCI Payment	Amount	Share of NCI
Clinical Center	\$197,409,339	40.4%
Center for Scientific Review	\$21,597,229	4.4%
Center for Information Technology	\$41,206,237	8.4%
Service & Supply Fund Assessment	\$228,904,169	46.8%
Other Research Services	\$0	0.0%
Other OD	\$0	0.0%
Total NCI Management Fund & SSF	\$489,116,975	100.0%

NIH FISCAL YEAR 2023 MANAGEMENT FUND AND SSF

(Whole Dollars)

Type	Amount	Percent
NCI	\$489,116,975	20.2%
Other NIH Institutes	\$1,930,388,810	79.8%
Total NIH Management Fund & SSF	\$2,419,505,784	100%

Special Sources of Funds

Cooperative Research and Development Agreements (CRADAs)

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Under a CRADA, the NIH laboratory can provide personnel, services, facilities, equipment, or other resources and the collaborator can provide funds, personnel, services, facilities, equipment or other material and/or technical resources. Importantly, the CRADA provides the non-Federal party the option to negotiate an exclusive license to the resultant CRADA Subject Invention(s). The CRADA is the primary legal mechanism the Federal government has to convey such rights in advance of an invention. The agreement has no mandatory length but often are written for 1 to 3 years, renewable at the mutual agreement of the parties.

NCI CRADA RECEIPTS DEPOSITED TO THE U.S. TREASURY

(Dollars in Thousands)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
2006	13,567	6,142	7,125
2007	12,584	9,410	8,360
2008	13,634	6,677	7,200
2009	13,111	5,466	4,765
2010	13,813	5,024	5,644
2011	13,150	8,582	5,894
2012	15,504	9,253	5,668
2013	10,587	11,226	8,470
2014	21,173	9,334	5,672
2015	24,835	15,772	11,670
2016	28,276	23,411	17,259
2017	40,647	27,033	20,990
2018	46,311	28,601	22,936

(Continued from previous page)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
2019	50,978	32,899	28,178
2020	53,825	33,776	28,683
2021	59,044	38,735	32,994
2022	71,091	22,856	11,301
2023	67,363	34,102	37,834

Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to support employees of the laboratory, further scientific exchange, and provide education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts at NCI and NIH. Royalties may be spent in the year of receipt and for two additional fiscal years.

NCI ROYALTY INCOME FUNDING HISTORY

(Dollars in Thousands)

Years	Collections*	Inventor Payments	Other Obligations
1991/1992	\$2,084	\$431	\$1,653
2001/2003	27,443	6,210	21,233
2005/2007	34,086	5,745	28,341
2006/2008	29,811	6,853	22,958
2007/2009	36,344	7,210	29,134
2008/2010	50,269	8,192	42,077
2009/2011	51,621	10,225	41,396
2010/2012	58,515	5,729	52,786
2011/2013	69,155	23,271	45,884

(Continued from previous page)

Years	Collections*	Inventor Payments	Other Obligations
2012/2014	84,876	33,279	51,597
2013/2015	91,324	48,433	42,891
2014/2016	112,668	33,487	79,181
2015/2017	122,037	30,605	91,432
2016/2018	115,096	27,316	87,780
2017/2019	112,611	27,233	85,378
2018/2020	86,231	15,539	70,692
2019/2021	70,400	5,370	65,030
² 2020/2022	24,541	7,244	17,297
² 2021/2023	34,142	6,130	28,012
³ 2022/2024	42,709	7,907	34,802
³ 2023/2025	34,856	6,638	28,218

* Collections do not include assessments by NIH.

² Amounts for 2020/2022 and 2021/2023 were corrected from prior reports.

³ 2022/2024 and 2023/2025 Inventor Payments and Other Obligations are estimates.

Stamp Out Breast Cancer Act

The Stamp Out Breast Cancer Act ([PL 105-41](#)) was enacted in August 1997 and has since been extended to July 2000 ([PL 106-253](#)), November 2005 ([PL 109-100](#)), December 2007 ([PL 110-150](#)), December 2011 ([PL 112-80](#)), December 2015 ([PL 114-99](#)) and recently until December 2027 ([PL 116-92](#)). This act allows postal customers the opportunity to contribute funds to breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service (USPS). Of the funds collected above the postage costs and administrative costs, the act requires the USPS to transfer 70% to NIH and 30% to the Department of Defense. As of September 2023, NCI has received \$66,586,050. NCI uses these funds for research projects directed towards breast cancer research. Thus far, five major programs have been funded, including the Insight Awards to Stamp Out Breast Cancer, the Breast Cancer Research Stamp Exceptional Opportunities Program, the Breast Cancer Premalignancy Program, a clinical trial to determine the risk of breast cancer recurrence, the Molecular and Cellular Characterization of Screen Detected Lesions Consortium, the Breast Cancer Weight Loss (BWEL), and the Tomosynthesis Mammographic Imaging Screening Trial (TMIST). In fiscal year 2023, \$3,423,048 million in stamp funds were obligated towards breast cancer research.

NCI BREAST CANCER STAMP FUNDING HISTORY

(Dollars in Thousands)

FY	Collected	Obligated	*Balance
1999	4,150	0	4,150
2000	3,101	3,499	3,753
2001	5,556	4,846	4,463
2002	3,595	1,129	6,929
2003	5,176	3,130	8,975
2004	4,814	3,472	10,317
2005	4,372	2,987	11,703
2006	4,468	6,896	9,274
2007	3,006	1,601	10,679
2008	4,856	2,122	13,413
2009	3,403	1,873	14,944

(Continued from previous page)

FY	Collected	Obligated	*Balance
2010	2,345	2,590	14,698
2011	2,049	1,977	14,770
2012	1,623	1,654	14,738
2013	1,404	1,337	14,805
2014	1,160	1,477	14,488
2015	1,251	1,635	14,105
2016	1,707	1,654	14,158
2017	1,387	1,640	13,905
2018	1,294	5,349	16,497
2019	1,450	2,518	15,429
2020	1,060	2,571	13,918
2021	1,112	1,000	14,030
2022	1,221	1,461	13,791
2023	1,028	3,423	11,395

*Balance includes carryover funds from the prior fiscal year that have not obligated.

Funding for Research Areas

NCI reports how appropriated funds are spent based on different categories or classifications, including specific cancer sites, cancer types, diseases related to cancer, as well as types of NCI research mechanisms. The table below identifies funding levels for frequently requested areas of cancer research.

The research areas in this table do not represent the entire NCI research portfolio. Moreover, funding for research areas often overlap, and therefore the total for all research areas does not add to the total NCI budget. For example, funding for a clinical trial on breast cancer would be included in both the “Breast Cancer” and the “Clinical Trials” lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine, and ovarian cancers, and relevant amounts would be included in the amounts for all three areas of cancer research. NCI provides estimated amounts based on initial budget data before final reconciliation is completed. After this analysis is done, years are marked “Actual” where figures often vary slightly from previously reported estimates.

FUNDING BY RESEARCH AREAS

(Dollars in Millions)

Disease Area	2016 Actual	2017 Actual	2018 Actual	2019 Actual	2020 Estimate	2021 Estimate	2022 Estimate
Total NCI Budget	\$5,206.2	\$5,636.4	\$5,927.7	\$5,992.3	\$6,383.3	\$6,467.0	\$6,833.6
AIDS	266.4	249.0	241.2	242.0	242.0	248.9	258.856
Brain & CNS	196.3	219.8	220.9	231.7	595.1	251.1	261.1
Breast Cancer	520.1	545.1	574.9	545.3	514.6	558.3	580.6
Cervical Cancer	65.6	68.0	71.5	86.0	69.3	73.7	76.6
Clinical Trials	801.0	806.6	889.8	794.3	843.0	824.6	857.6
Colorectal Cancer	212.2	208.4	256.0	238.8	211.6	248.0	257.9
Head and Neck Cancers	58.9	63.6	62.1	71.5	49.7	69.0	55.1

(Continued from previous page)

Disease Area	2016 Actual	2017 Actual	2018 Actual	2019 Actual	2020 Estimate	2021 Estimate	2022 Estimate
Hodgkin Disease	12.8	13.0	13.3	12.2	14.3	15.9	16.5
Leukemia	241.0	250.5	258.3	256.6	244.5	276.0	287.0
Liver Cancer	75.7	72.7	94.6	107.8	96.3	111.5	116.0
Lung Cancer	283.8	320.6	350.1	418.4	402.8	459.0	477.4
Melanoma	142.9	153.2	158.4	191.9	155.6	179.2	186.4
Multiple Myeloma	52.1	60.7	61.5	58.2	43.3	51.3	53.4
Non-Hodgkin Lymphoma	116.7	119.5	121.0	120.4	119.5	137.7	143.2
Ovarian Cancer	95.3	109.8	120.8	121.5	116.5	134.7	140.1
Pancreatic Cancer	152.6	178.3	182.1	187.0	178.5	218.1	226.8
Prostate Cancer	241.0	233.0	239.1	244.8	209.4	269.7	280.5
Stomach Cancer	13.3	13.4	14.2	14.8	10.6	15.4	16.0
Uterine Cancer	16.8	17.5	17.5	17.9	13.6	14.4	15.0

These figures were created using NCI's coding methodology. More information about this methodology, as well as the research projects associated with these and other disease area categories, are available on the [NCI Funded Research Portfolio](#) website.


The fiscal year 2022 funds available to NCI totaled \$6.8 billion (includes \$216 million in Cures Act funding), reflecting an increase of 5.7%, or \$366.6 million from the previous fiscal year. For fiscal year 2022 NCI Research Project Grants funding policy and for more information on NCI's grant funding please see [NCI's Division of Extramural Activities](#).

NCI Extramural Programs

The NCI uses most of its budget to fund extramural grants and contracts. The following links provide information about Fiscal Year 2023 extramural funding by grant activity, institution, state, and country.

Research Project Grants (RPGs)

In fiscal year 2023, 1,369 competing RPGs were funded. Over 69.1% of competing dollars supported grants awarded within the established payline and requests for applications (RFAs) and the remainder supported grants as an exception to the fundable range. RFA funds accounted for 10.3% of the fiscal year 2023 competing dollars.



Includes Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards. Fiscal years 2020-2023 includes Cancer Moonshot funding.

RPGs Summary, Fiscal Years 2022–2023

RPG AWARDS FUNDED

(Dollars in Thousands)

RPG Awards Funded	2022 No. or %	2022 Amount	2023 No. or %	2023 Amount
Total Funding for RPGs	5,497	\$2,966,486	5,736	\$3,145,237
SBIR/STTR	207	\$151,396	228	\$175,373
Funding for RPGs without SBIR/STTR Program	5,290	\$2,815,090	5,508	\$2,969,864
Continuation or Noncompeting Grants Funded	3,933	\$2,013,233	4,139	\$2,125,093
Competing Grants Funded	1,357	\$665,061	1,369	\$697,786
Administrative Supplements	325	\$34,325	354	\$39,659
Partial assessment for DHHS Program Evaluation		\$102,471		\$107,326

FUNDS SET ASIDE WITHIN COMPETING DOLLARS

(Dollars in Thousands)

Grant Category	R01 or Share	2022 No. or %	2022 Amount	2023 No. or %	2023 Amount
Grants within Paylines		992	\$430,938	1,018	\$481,920
	Traditional R01	710	\$371,261	776	\$428,468
RFA Grants		139	\$82,897	115	\$71,919

(Continued from previous page)

Grant Category	R01 or Share	2022 No. or %	2022 Amount	2023 No. or %	2023 Amount
	Share of Competing Grant Funds	12.5%		10.3%	
Exception Grants		365	\$234,123	351	\$215,866
	Share of Competing Grant Funds	35.2%		30.9%	

COMPETING RPGS

Statistical Measure	2022	2023
Total Competing Application Requests*	8,932	8,618
Funding Success Rate	15%	16%
Percentile Funding for R01 grants	16th	17th
Average Cost-Competing	\$490	\$510
Average Reduction from Recommended/Requested Levels	-14%	-14%


*Excludes SBIR/STTR

Includes fiscal year 2023 Cancer Moonshot funding. Includes fiscal years 2022 through 2017 Moonshot carryover obligations.

Traditional R01 line (includes Trad R01 and converted R37)

RPGs Funding Mechanisms

Percent Share of Total RPG Funds, FY 23



cancer.gov

The “Other” category includes DP1, DP2, DP5, R00, R37, U01, U19, UH2, UH3, UG3, UA5, R50, UM1, R15, R55, R56 and R61 activities.

GRANT FUNDING PAYLINES

RPG Mechanism	2022	2023	Description
R01 Traditional Grants	11th & 16th	12th & 17th	Percentile
P01 Program Projects	17% Reduction	17% Reduction	SPL Selected*
R03 Small Grants	25	25	Impact Score
R15 Academic Research	25	25	Impact Score
R21 Exploratory Phase I	9th	9th	Percentile
R33 Exploratory Phase II	N/A	N/A	SPL Selected*
R41/R42 STTR	24	26	Impact Score
R43/R44 SBIR	24	27	Impact Score

*SPL = Scientific Program Leaders (NCI)

RPGs Requested and Awarded

The following table displays requested and awarded RPGs and the success rate for fiscal years 2022 and 2023. These numbers include Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards. The Download the Data link contains data for the prior ten years.

RPGS REQUESTED, AWARDED, AND SUCCESS RATE

(Dollars in Thousands)

Fiscal Year	Type	Number Requested	Amount Requested	Number Awarded	Amount Awarded	Success Rate
2022	Competing New	9,580	\$4,902,539	1,324	\$635,623	14.8%
	Competing Renewal	431	\$335,464	154	\$107,730	
	Competing Supplement	28	\$8,867	12	\$3,363	
	Competing Subtotal	10,039	\$5,246,870	1,490	\$746,715	
	Non-Competing			4,007	\$2,219,770	
	FY 2022 RPG Total			5,497	\$2,966,486	
2023	Competing New	9,302	\$4,888,297,784	1,319	\$653,918	15.4%
	Competing Renewal	427	\$341,237,643	179	\$130,281	
	Competing Supplement			0	\$0	
	Competing Subtotal	9,729	\$5,229,535,427	1,498	\$784,199	

(Continued from previous page)

Fiscal Year	Type	Number Requested	Amount Requested	Number Awarded	Amount Awarded	Success Rate
	Non-Competing			4,238	\$2,253,712	
	FY 2023 RPG Total			5,736	\$3,037,911	

Includes Small Business Innovation Research and Small Business Technology Transfer Awards.

Fiscal years 2023 through 2020 figures includes Cancer Moonshot funding data.

Success rate is the number of awarded grants divided by the number of awards requested.

Includes fiscal year 2023 Cancer Moonshot funding. Includes fiscal years 2022 through 2017 Moonshot carryover obligations.

RPG Awards by Grant Activity Codes

This table displays awarded research project grants (RPG) data by grant activity code and count. Please visit [NIH Activity Codes](#) for more information on the descriptions.

RPGS AVERAGE COST, FISCAL YEARS 2013–2023

(Dollars in Thousands)

Year	Total No. Awarded	Total Amount	Average Cost
2013	4,816	\$1,924,803	\$400
2014	4,814	\$1,939,623	\$403
2015	4,767	\$2,019,308	\$424
2016	4,666	\$2,068,869	\$443
*2017	4,663	\$2,195,184	\$471
*2018	4,780	\$2,366,530	\$495
*2019	4,984	\$2,456,156	\$493
*2020	5,070	\$2,677,206	\$528
**2021	5,221	\$2,739,345	\$525
*2022	5,497	\$2,864,015	\$521
*2023	5,736	\$3,037,911	\$530

*From fiscal year 2017 onward, RFAs will be accounted for in the actual grant mechanism categories under which they fall.

*Fiscal years 2023 through 2017 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2022 through 2018.

**Fiscal year 2021 includes multi-year funded grants with a 1 year average cost estimation.

RPG AWARDS BY GRANT ACTIVITY CODES, FISCAL YEARS 2022–2023

(Dollars in Thousands)

Grant Code	2022 Number	2022 Amount	2023 Number	2023 Amount
R01	3,584	\$1,737,550	3,725	\$1,864,401
DP1	0	\$0	0	\$0
DP2	0	\$526	0	\$356
DP5	0	\$0	0	\$0
P01	99	\$200,007	96	\$197,631
R00	93	\$22,788	104	\$25,555
R37	277	\$128,583	343	\$164,733
U01	325	\$239,325	321	\$236,674
U19	7	\$12,400	7	\$12,552
UH34			1	\$284
UH2	10	\$2,117	5	\$1,057
R34			3	\$881
R35	152	\$146,781	133	\$127,082
R50	72	\$12,716	94	\$16,474
UH3	26	\$16,703	30	\$24,463
UA5	0	\$0	0	\$0
UM1	14	\$52,568	21	\$53,731
UG3	10	\$9,020	3	\$4,126
R03	115	\$9,244	108	\$9,508

(Continued from previous page)

Grant Code	2022 Number	2022 Amount	2023 Number	2023 Amount
R21	445	\$97,456	433	\$93,605
R33	33	\$12,809	43	\$16,046
R15	24	\$10,620	20	\$9,050
R55	0	\$0	0	\$0
R56	4	\$969	5	\$1,220
R61	1	\$437	13	\$3,108
RC2	0	\$0	0	\$0
SBIR/STTR	207	\$151,386	228	\$175,373
Total	5,497	\$2,864,015	5,736	\$3,037,911

RPG Activity Codes with a "0" count displayed for No. are grants where NCI did not take the grant award count for the funding since NCI was not the Primary IC funding the award.

*From fiscal year 2017 onward, RFAs will be accounted for in the actual grant mechanism categories under which they fall.

*Fiscal years 2023 through 2017 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2022 through 2018.

**Fiscal year 2021 includes multi-year funded grants with a 1 year average cost estimation.

Grants to NCI-Designated Cancer Centers

NCI-Designated Cancer Centers are institutions dedicated to research to develop more effective approaches to prevent, diagnose, and treat cancer. [Find an NCI-Designated Cancer Center](#) near you and learn about its patient services and research capabilities.

The grant count and amounts include multi-year funded awards and the fiscal year 2023 Cancer Moonshot funds, excludes carryover obligations for fiscal years 2022 through 2017.

NCI-DESIGNATED CANCER CENTER TOTALS, FISCAL YEAR 2023

(Dollars in Thousands)

Mechanism	Count	Amount
*Total P30 Core Grants	72	\$345,557
Planning Grants (P20s)	10	\$2,777
**Other Cancer Center Grants	0	\$5,169
Total Cancer Centers	82	\$353,503

*Includes multi-year funded awards.

**Per the National Institutes of Health's Office of Extramural Research (OER) "Count Rules" & guidelines policy, updated each fiscal year with limits based on the cost center and division; this category is to be reported as zero.

NCI-DESIGNATED CANCER CENTERS BY STATE (P30 CORE GRANTS), FISCAL YEAR 2023

(Dollars in Thousands)

State	Grantee Institution	Code	Count	Amount
Alabama	University of Alabama at Birmingham	Comprehensive Core	1	\$5,907
Arizona	University of Arizona	Comprehensive Core	1	\$3,937
California	Beckman Research Institute/City of Hope	Comprehensive Core	1	\$4,789
	Salk Institute for Biological Studies	Basic Core	1	\$3,067
	Sanford Burnham Prebys Medical Discovery Institute	Basic Core	1	\$4,582
	Stanford University	Comprehensive Core	1	\$4,349
	University of California, Davis	Comprehensive Core	1	\$3,551
	University of California, Los Angeles	Comprehensive Core	1	\$6,004
	University of California, San Diego	Comprehensive Core	1	\$5,241
	University of California, San Francisco	Comprehensive Core	1	\$8,426
	University of California, Irvine	Comprehensive Core	1	\$2,343
	University of Southern California	Comprehensive Core	1	\$7,279

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Colorado	University of Colorado, Denver	Comprehensive Core	1	\$4,332
Connecticut	Yale University	Comprehensive Core	1	\$4,740
District of Columbia	Georgetown University	Comprehensive Core	1	\$2,590
Florida	H. Lee Moffitt Cancer Center & Research Institute	Comprehensive Core	1	\$5,011
	University of Florida	Clinical Core	1	\$2,331
	University of Miami School of Medicine	Clinical Core	1	\$2,341
Georgia	Emory University	Comprehensive Core	1	\$3,857
Hawaii	University of Hawai'i at Manoa	Clinical Core	1	\$2,191
Illinois	Northwestern University at Chicago	Comprehensive Core	1	\$6,528
	University of Chicago	Comprehensive Core	1	\$4,541
Indiana	Indiana University at Indianapolis	Comprehensive Core	1	\$2,747
	Purdue University	Basic Core	1	\$1,860

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Iowa	University of Iowa	Comprehensive Core	1	\$2,696
Kansas	University of Kansas Medical Center	Comprehensive Core	1	\$2,809
Kentucky	University of Kentucky	Comprehensive Core	1	\$2,700
Maine	Jackson Laboratory	Basic Core	1	\$2,507
Maryland	Johns Hopkins University	Comprehensive Core	1	\$9,007
	University of Maryland Baltimore	Comprehensive Core	1	\$2,664
Massachusetts	Dana-Farber Cancer Institute	Comprehensive Core	1	\$13,518
	Massachusetts Institute of Technology	Basic Core	1	\$3,755
Michigan	University of Michigan at Ann Arbor	Comprehensive Core	1	\$7,540
	Wayne State University	Comprehensive Core	1	\$2,936
Minnesota	Mayo Clinic in Rochester	Comprehensive Core	1	\$5,930
	University of Minnesota	Comprehensive Core	1	\$4,252
Missouri	Washington University	Comprehensive Core	1	\$6,766

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Nebraska	University of Nebraska Medical Center	Clinical Core	1	\$3,519
New Hampshire	Dartmouth College	Comprehensive Core	1	\$3,179
New Jersey	Rutgers Biomedical and Health Sciences	Comprehensive Core	1	\$3,225
New Mexico	University of New Mexico Health Science Center	Comprehensive Core	1	\$2,627
New York	Albert Einstein College of Medicine Yeshiva University	Comprehensive Core	1	\$4,088
	Cold Spring Harbor Laboratory	Basic Core	1	\$4,495
	Columbia University Health Sciences	Comprehensive Core	1	\$5,808
	Icahn School of Medicine at Mount Sinai	Clinical Core	1	\$2,838
	New York University School of Medicine	Comprehensive Core	1	\$4,196
	Roswell Park Cancer Institute Corp	Comprehensive Core	1	\$4,395
	Memorial Sloan Kettering Institute for Cancer Research	Comprehensive Core	1	\$14,034

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
North Carolina	Duke University	Comprehensive Core	1	\$6,455
	University of North Carolina Chapel Hill	Comprehensive Core	1	\$8,047
	Wake Forest University Health Sciences	Comprehensive Core	1	\$2,493
Ohio	Case Western Reserve University	Comprehensive Core	1	\$5,673
	Ohio State University	Comprehensive Core	1	\$5,862
Oklahoma	University of Oklahoma Health Sciences Center	Clinical Core	1	\$3,351
Oregon	Oregon Health & Science University	Comprehensive Core	1	\$3,383
Pennsylvania	Research Institute of Fox Chase Cancer Center	Comprehensive Core	1	\$0
	Thomas Jefferson University	Clinical Core	1	\$2,871
	University of Pennsylvania	Comprehensive Core	1	\$9,999
	University of Pittsburgh	Comprehensive Core	1	\$5,996
	Wistar Institute	Basic Core	1	\$2,965
South Carolina	Medical University of South Carolina	Clinical Core	1	\$2,343

(Continued from previous page)

State	Grantee Institution	Code	Count	Amount
Tennessee	St. Jude Children's Research Hospital	Comprehensive Core	1	\$7,691
	Vanderbilt University Medical Center	Comprehensive Core	1	\$7,521
Texas	Baylor College of Medicine	Comprehensive Core	1	\$3,611
	University of Texas Health Science Center	Clinical Core	1	\$2,192
	University of Texas MD Anderson Cancer Center	Comprehensive Core	1	\$11,634
	University of Texas Southwestern Medical Center	Comprehensive Core	1	\$4,355
Utah	University of Utah	Comprehensive Core	1	\$5,127
Virginia	University of Virginia	Comprehensive Core	1	\$2,603
	Virginia Commonwealth University	Comprehensive Core	1	\$2,829
Washington	Fred Hutchinson Cancer Research Center	Comprehensive Core	1	\$10,609
Wisconsin	University of Wisconsin-Madison	Comprehensive Core	1	\$5,919
Total P30 Core Grants			72	\$345,557

Specialized Programs of Research Excellence (SPOREs)

In 1992, NCI established the Specialized Programs of Research Excellence (SPORE). The Translational Research Program (TRP) is the home of the SPOREs, a cornerstone of NCI's efforts to promote collaborative, interdisciplinary translational cancer research. SPORE grants involve both basic and clinical/applied scientists, and support projects that will result in new and diverse approaches to the prevention, early detection, diagnosis, and treatment of human cancers.

Each SPORE focuses on a specific organ site, such as breast or lung cancer, or on a group of highly related cancers, such as gastrointestinal cancers. SPOREs are designed to enable the rapid and efficient movement of basic scientific findings into clinical settings, as well as to determine the biological basis for observations made in individuals with cancer or in populations at risk for cancer.

For more information on organ sites, please visit the [Translational Research Program](#).

The NCI Funded Research Portfolio (NFRP) web site contains additional information about the SPORE grants listed below that have been funded by NCI. The NFRP provides access to various NCI budget reports that contain information about research funding according to specific research categories.

For more detailed information on these SPORE grants, visit the [NCI Funded Research Portfolio \(NFRP\)](#).

FISCAL YEAR 2023 FUNDING FOR SPORE GRANTS

(Whole Dollars)

Mechanism	Site	Amount
P50 & P20 SPOREs	Brain	\$13,225,565
	Breast	\$11,143,857
	Cervical	\$1,672,035
	Disparities/Breast & Lung	\$1,673,168
	Endometrial	\$2,384,742
	Epigenetic	\$4,619,587
	Gastrointestinal	\$6,855,962
	Head and Neck	\$5,898,494
	Hyperactive RAS	\$2,139,494
	Kidney	\$4,361,627
	Leukemia	\$4,486,023
	Liver	\$3,035,095
	Lung	\$12,815,820
	Lymphoma	\$2,048,062
	Multiple Myeloma	\$4,233,641
	Ovarian	\$9,454,021
	Pancreas	\$6,557,382

(Continued from previous page)

Mechanism	Site	Amount
P50 & P20 SPOREs	Prostate	\$14,095,451
	Radiation	\$2,066,150
	Sarcoma	\$918,606
	Skin	\$9,849,435
	Total P50 SPOREs	\$123,534,217
Co-funded	Head & Neck	\$575,000
	Total Co-funded	\$575,000
Total Number of SPOREs, Total SPORE Funding		\$124,109,217

Total funding shown represents the SPORE program using relevant co-funded grants external to NCI.

Includes fiscal year 2023 Cancer Moonshot funding and excludes all carryover obligations for fiscal years 2022 through 2018.


Dr. Ruth L. Kirschstein National Research Service Awards (NRSA)

This trainee award program is named after Dr. Ruth L. Kirschstein, a polio vaccine researcher and a champion of research training and inclusion of underrepresented individuals in the scientific workforce. Dr. Kirschstein was the first woman to become director of an NIH institute.

The NCI Ruth L. Kirschstein National Research Service Award (NRSA) program helps ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to meet the nation's biomedical, behavioral, and clinical research needs.

National Research Service Awards (NRSAs) Predoctoral and Postdoctoral Trainees (Full-Time Trainee Positions)

Fiscal Years 2013 - 2023




cancer.gov

Research Career Awards “K” Program

The NCI career development (K) awards program includes a broad range of funding mechanisms and provides scientists with support to further develop their cancer research careers, transition to independence, expand their existing research programs, or mentor junior investigators. The K awards are a significant component of NCI’s training effort.

Total Number of K Awards


Fiscal Years 2012 - 2023



cancer.gov

Percent of Total Research Career Awards Funded

Fiscal Year 2023



- K00 Post-Doc-Fellow Awards
- K01 Research Scientist Development Award
- K05 Research Scientist Award
- K07 Preventive Oncology
- K08 Clinical Investigator
- K12 Institutional Clinical Oncology Research
- K22 Transitional Career Development
- K23 Patient-Oriented Career
- K24 Patient-Oriented Career - Mid Career
- K25 Mentored Quantitative Research Career Development Award
- K43 Mentored Career Devel/Temin Intl Career
- K99 NIH Pathway to Independence Awards

cancer.gov

Grant and Contract Awards

The following displays the number and dollar amount of grant and contract awards by state and country with details for institutions receiving more than \$15 million in support from NCI.

Grants are used when no substantial programmatic involvement is anticipated between NCI and the grant recipient during performance of the financially assisted activities and when there is no expectation on the part of NCI of a specified service or product for NCI.


Contracts are used to procure cancer research services and other resources that the federal government needs to advance the NCI cancer research mission.

Grant and contract data includes fiscal year 2023 (FY23) Cancer Moonshot funds and excludes FY21 through 2018 Cancer Moonshot carryover obligations and the Breast Cancer Stamp. Moving forward, grants and contract awards will include all NCI obligations for grants and contract awards for each fiscal year. Per the National Institutes of Health's Office of Extramural Research, "Count Rules" and guidelines policy are updated each fiscal year with limits based on the cost center and division. A "0" indicates an award funded by other NIH Institutes that NCI also co-funded.

Grant and Contract Awards by State and Institution

In the map graphic below, grant and contract awards are presented by state. The table below the graphic provides information for U.S. territories. Within each state, hover to view the total amount awarded and click to view detailed data on institutions that received more than \$15 million in support from NCI during fiscal year 2023. For purposes of the NCI Budget Fact Book, institutions include universities, cancer centers, and hospitals.

Grant and Contract Awards by State and Institution, FY 2023



GRANT AWARDS BY STATE, FISCAL YEAR 2023

(Whole Dollars)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Alabama	83	\$41,921,018	0	\$0	83	\$41,921,018
Alaska	1	\$755,274	0	\$0	1	\$755,274
Arizona	71	\$39,505,441	0	\$140,000	71	\$39,645,441
Arkansas	18	\$6,371,018	0	\$0	18	\$6,371,018
California	1020	\$628,231,958	18	\$26,993,462	1038	\$655,225,420

(Continued from previous page)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Colorado	100	\$44,746,685	2	\$59,099	102	\$44,805,784
Connecticut	135	\$65,982,608	3	\$3,678,660	138	\$69,661,268
Delaware	7	\$5,671,496	0	\$0	7	\$5,671,496
D.C.	68	\$35,896,190	10	\$2,399,545	78	\$38,295,735
Florida	231	\$110,489,282	3	\$1,597,110	234	\$112,086,392
Georgia	141	\$69,202,094	4	\$5,588,699	145	\$74,790,793
Hawaii	20	\$17,892,286	2	\$1,896,674	22	\$19,788,960
Idaho	0	\$280,294	1	\$588,337	1	\$868,631
Illinois	243	\$140,491,239	8	\$9,036,174	251	\$149,527,413
Indiana	85	\$42,147,432	0	\$0	85	\$42,147,432
Iowa	35	\$17,977,800	2	\$4,347,101	37	\$22,324,901
Kansas	30	\$15,702,744	0	\$0	30	\$15,702,744
Kentucky	48	\$21,168,960	4	\$3,564,005	52	\$24,732,965
Louisiana	28	\$13,895,499	2	\$1,950,064	30	\$15,845,563
Maine	17	\$10,200,411	0	\$0	17	\$10,200,411
Maryland	201	\$212,530,007	56	\$693,238,932	257	\$905,768,939
Massachusetts	652	\$385,769,193	3	\$1,405,172	655	\$387,174,365
Michigan	214	\$104,170,166	1	\$47,805	215	\$104,217,971
Minnesota	182	\$119,390,522	6	\$937,523	188	\$120,328,045
Missouri	173	\$96,815,698	112	\$13,901,993	285	\$110,717,691
Montana	3	\$1,562,267	0	\$0	3	\$1,562,267

(Continued from previous page)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Nebraska	41	\$17,556,150	9	\$165,211	50	\$17,721,361
Nevada	3	\$2,647,005	0	\$0	3	\$2,647,005
New Hampshire	36	\$19,106,606	0	\$0	36	\$19,106,606
New Jersey	73	\$37,865,951	6	\$12,377,743	79	\$50,243,694
New Mexico	19	\$12,121,019	2	\$3,022,414	21	\$15,143,433
New York	942	\$545,735,711	7	\$12,873,023	949	\$558,608,734
North Carolina	315	\$154,164,481	8	\$1,159,524	323	\$155,324,005
North Dakota	1	\$199,295	0	\$0	1	\$199,295
Ohio	270	\$147,295,258	3	\$816,591	273	\$148,111,849
Oklahoma	41	\$18,884,297	1	\$1,140,397	42	\$20,024,694
Oregon	78	\$50,947,840	83	\$3,270,068	161	\$54,217,908
Pennsylvania	485	\$320,161,957	15	\$2,607,635	500	\$322,769,592
Rhode Island	32	\$7,219,763	0	\$0	32	\$7,219,763
South Carolina	67	\$35,880,149	0	\$0	67	\$35,880,149
South Dakota	3	\$1,776,787	0	\$0	3	\$1,776,787
Tennessee	194	\$127,018,869	2	\$58,310	196	\$127,077,179
Texas	656	\$342,880,297	5	\$5,158,463	661	\$348,038,760
Utah	74	\$36,175,034	3	\$4,292,160	77	\$40,467,194
Vermont	12	\$6,596,560	0	\$0	12	\$6,596,560
Virginia	118	\$72,244,078	18	\$58,171,754	136	\$130,415,832

(Continued from previous page)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Washington	225	\$159,658,477	4	\$6,770,204	229	\$166,428,681
West Virginia	8	\$3,540,909	0	\$0	8	\$3,540,909
Wisconsin	112	\$80,442,413	4	\$7,729,694	116	\$88,172,107

Includes fiscal year 2023 Cancer Moonshot funding and excludes all carryover obligations for fiscal years 2022 through 2018.

Per the National Institutes of Health's Office of Extramural Research (OER) "Count Rules" & guidelines policy are updated each fiscal year with limits based on the cost center and division. A "0" indicates an award funded by other NIH Institutes that NCI also co-funded.

GRANT AWARDS BY TERRITORY, FISCAL YEAR 2022

(Whole Dollars)

Country	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Guam	1	\$1,329,430	0	\$0	1	\$1,329,430
Puerto Rico	9	\$6,434,665	0	\$0	9	\$6,434,665

Grant and Contract Awards by Country

NCI funds and co-funds cancer research all over the world. The table below lists number and dollar amount of grant and contract awards by country.

GRANT AND CONTRACT AWARDS BY COUNTRY, FISCAL YEAR 2023

(Whole Dollars)

Country	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Argentina	1	\$246,493	0	\$0	1	246,493
Australia	4	\$2,766,718	0	\$0	4	2,766,718
Canada	12	\$10,351,914	1	\$215,500	13	10,567,414
Ethiopia	0	\$250,000	0	\$0	0	250,000
France	8	\$4,080,322	1	\$7,871,125	9	11,951,447
Germany	2	\$1,107,340	0	\$0	2	1,107,340
Israel	1	\$191,085	0	\$0	1	191,085
Jamaica	0	\$50,000	0	\$0	0	50,000
Kenya	1	\$216,000	0	\$0	1	216,000
Nigeria	0	\$133,550	0	\$0	0	133,550
Rwanda	1	\$226,299	0	\$0	1	226,299
South Africa	4	\$693,714	0	\$0	4	693,714
Spain	1	\$307,531	0	\$0	1	307,531
Switzerland	1	\$1,136,842	0	\$0	1	1,136,842
Tanzania U Rep	0	\$75,000	0	\$0	0	75,000
Uganda	1	\$312,395	0	\$0	1	312,395
United Kingdom	14	\$3,404,923	0	\$0	14	3,404,923
Total	51	\$25,550,126	2	\$8,086,625	53	\$33,636,751

Per the National Institutes of Health's Office of Extramural Research (OER) "Count Rules" & guidelines policy are updated each fiscal year with limits based on the cost center and division. A "0" indicates an award funded by other NIH Institutes that NCI also co-funded.

NCI Historical Trends

Established in 1937, the National Cancer Institute (NCI) was among the first Institutes of the National Institutes of Health (NIH). From the outset, NCI served as a scientific cornerstone of the NIH. The following links provide information about the history of NCI appropriations and the Professional Judgment (Bypass) Budget, as well as data on funding trends and staffing levels.


NCI Professional Judgment Budget, President's Budget and Appropriations

Professional Judgment Budget, President's Budget, and Enacted Appropriations Comparison

This graph displays a historical view of the Professional Judgment Budget, the President's Budget, and the Enacted Appropriations for NCI from fiscal years 1974 through 2025. The National Cancer Act gives the NCI director special authority to submit an annual Professional Judgment Budget, sometimes referred to as the "Bypass Budget," directly to the President and Congress. This budget reflects NCI cancer research priorities and identifies areas of potential investment in cancer research. The President's Budget is an annual report prepared by the White House, and in coordination with federal agencies, proposing funding levels for the federal government, including for NIH and NCI, according to the President's priorities. Congress reviews the Professional Judgment Budget and the President's Budget, and then conducts its own inquiries and hearings to develop and pass an appropriations bill to fund the government. When the bill is signed into law by the President, the Enacted Appropriation levels become available for NCI's cancer research activities.

Professional Judgment Budget, President's Budget, and Enacted Appropriation Comparison

Fiscal Years 1974 - 2025



FY	Professional Judgement Budget*	President's Budget*	Enacted Appropriation*
1974	640,031	500,000	551,192
1975	750,000	600,000	691,666
1976	898,500	605,000	914,628
1977	948,000	687,670	815,000
1978	955,000	818,936	872,388
1979	1,036,000	878,802	937,129
1980	1,055,000	936,958	1,000,000
1981	1,170,000	1,007,800	989,355
1982	1,192,000	1,025,946	986,617

(Continued from previous page)

FY	Professional Judgement Budget*	President's Budget*	Enacted Appropriation*
1983	1,197,000	955,449	987,642
1984	1,074,000	986,681	1,081,581
1985	1,189,000	916,485	1,183,806
1986	1,460,000	1,126,012	1,264,159
1987	1,570,000	1,158,089	1,402,837
1988	1,700,000	1,302,823	1,469,327
1989	2,080,000	1,468,256	1,593,536
1990	2,195,000	1,494,741	1,664,000
1991	2,410,000	1,694,059	1,766,324
1992	2,612,000	1,810,230	1,989,278
1993	2,775,000	2,010,439	2,007,483
1994	3,200,000	2,142,122	2,082,267
1995	3,600,000	1,967,709	2,135,119
1996	3,640,000	1,994,007	2,251,084
1997	2,977,000	2,060,392	2,382,532
1998	2,702,500	2,217,482	2,547,314
1999	3,191,000	2,528,760	2,927,187
2000	3,873,000	2,732,795	3,332,317
2001	4,135,000	3,249,730	3,757,242

(Continued from previous page)

FY	Professional Judgement Budget*	President's Budget*	Enacted Appropriation*
2002	5,030,000	4,177,203	4,190,405
2003	5,690,000	4,673,510	4,622,394
2004	5,986,000	4,770,519	4,770,519
2005	6,211,000	4,870,025	4,865,525
2006	6,170,000	4,841,774	4,841,774
2007	5,949,714	4,753,609	4,797,639
2008	5,865,788	4,782,114	4,890,525
2009	6,028,386	4,809,819	4,968,973
2010	7,193,393	5,150,170	5,103,388
2011	6,199,666	5,264,643	5,103,388
2012	5,869,857	5,196,136	5,081,788
2013	5,833,010	5,068,864	5,072,183
2014		5,125,951	4,923,238
2015		4,930,715	4,950,396
2016	5,754,000	5,098,479	5,214,701
2017	5,453,000	5,893,509	5,689,329
2018		4,474,222	5,964,800
2019	6,380,000	5,626,312	6,143,892
2020	6,522,000	5,246,737	6,440,442

(Continued from previous page)

FY	Professional Judgement Budget*	President's Budget*	Enacted Appropriation*
2021	6,928,000	5,881,173	6,559,852
2022	7,609,000	6,733,302	6,912,522
2023	7,766,000	6,713,851	7,320,159
2024	9,988,000	7,820,159	
2025	11,466,000	7,839,141	

* Dollars in thousands

- The Professional Judgment Budget was not released in fiscal years 2014, 2015, or 2018. To learn more about this authority and view the budget archive, please visit NCI's [About the Annual Plan](#) and [Budget Proposal page](#).
- The fiscal years 2017 and 2018 Enacted Appropriated budget includes \$300,000,000 of Cancer MoonshotSM funding. \$680,000,000 and \$300,000,000 of Cancer MoonshotSM funding are also included in the fiscal years 2017 and 2018 President's Budget. \$400,000,000, \$195,000,000, \$195,000,000 of Cancer MoonshotSM funding are included in the fiscal years 2019, 2020, and 2021 Enacted Appropriated levels, respectively. The Professional Judgment Budget and President's Budget also includes \$400,000,000, \$195,000,000, \$195,000,000, \$194,000,000 and \$216,000,000 of Cancer MoonshotSM funding in fiscal years 2019, 2020, 2021, 2022, and 2023, respectively.
- The Enacted Appropriation levels do not include potential adjustments such as Rescissions, Sequestrations, Supplemental funding, or Secretary's Transfers that may have impacted the amount available for NCI expenditure.

NCI Appropriations

NCI receives its budget from the United States Congress as part of the federal budget process for the Department of Health and Human Services and NIH.

The NCI budget for fiscal year 2021 (October 1, 2020 through September 30, 2021) is \$6.56 billion. During the period from 2010 through 2021, the NCI budget averaged \$5.52 billion per year.

The NCI budget for fiscal year 2022 (October 1, 2021 through September 30, 2022) is \$6.91 billion. During the period from 2010 through 2022, the NCI budget averaged \$5.62 billion per year.

The NCI budget for fiscal year 2023 (October 1, 2022 through September 30, 2023) is \$7.32 billion. During the period from 2010 through 2023, the NCI budget averaged \$5.75 billion per year.

APPROPRIATIONS OF THE NCI, 1938–2023

(Whole Dollars)

Fiscal Years	Amount	Notes
1938–2002	\$52,940,982,220	
2003	\$4,622,394,000	Prior to reductions in PL 108-7(-\$30,046,000 for the enacted rescission and \$2,000 lapse). Includes \$263,442,000 of AIDS funding.
2004	\$4,770,519,000	Prior to reductions in PL 108-199(-\$3,136,000 for Labor/HHS/ED rescission; \$28,128,000 for across the board reduction; -\$15,357,000 NIH 1% transfer assessment, and \$5,000 lapse). Includes \$266,975,000 of AIDS funding.
2005	\$4,865,525,000	Prior to reductions in PL 108-447(\$38,914,000 .8% across the board reduction; -\$1,353,000 for Labor/HHS/ED rescission; -\$30,505,000 NIH 1% transfer assessment, and \$9,000 lapse). Includes \$265,907,000 of AIDS funding.
2006	\$4,841,774,000	Prior to reductions in PL 109-149 (-\$48,418,000 for Labor/HHS/ED rescission; -\$3,293,000 HHS transfer for CMS activities; -\$42,834,000 NIH 1% transfer for roadmap activities, and \$4,000 lapse). Includes \$253,666,000 of AIDS funding.

(Continued from previous page)

Fiscal Years	Amount	Notes
2007	\$4,797,639,000	Prior to reductions in PL 110-5 (-\$5,015,000 NIH transfer for GEI activities, and \$9,000 lapse). Includes \$253,666,000 of AIDS funding.
2008	\$4,890,525,000	Prior to -\$85,437,000 rescission and \$3,091,000 in NIH transfer activities. Includes supplemental appropriation of \$25,559,000. Includes \$258,499,000 of AIDS funding.
2009	\$4,968,973,000	Prior to reductions in PL 111-8 (-\$2,042,631 NIH transfer for activities, and \$4,000 lapse). Includes \$265,882,000 of AIDS funding.
2010	\$5,103,388,000	Prior to -\$760,000 HHS Secretary's transfer, -\$4,459,000 in NIH transfer for activities, and \$22,000 lapse. Includes \$272,130,000 of AIDS funding.
2011	\$5,103,388,000	Prior to -\$44,810,787 rescission and \$472,000 lapse. Includes \$269,953,000 of AIDS funding.
2012	\$5,081,788,000	Prior to \$9,605,579 rescission, -\$1,445,000 HHS Secretary's transfer, -\$3,342,000 HHS Secretary's transfer for Alzheimer's research, and \$54,000 lapse. Includes \$271,692,000 of AIDS funding.
2013	\$5,072,183,000	Prior to -\$254,589,000 under sequestration (Budget Control Act, 2011, PL 112-25), -\$10,144,367 rescission, -\$28,044,000 HHS Secretary's transfer and +\$9,714,000 restored from the National Children's Study and National Eye Institute HIV/AIDS funding, and \$106,000 lapse. Includes \$261,550,000 of AIDS funding.
2014	\$4,923,238,000	Prior to -\$12,359,000 HHS Secretary's transfer, -\$965,000 HHS Secretary's Cybersecurity Transfer (authorized by section 206 of P.L. 113-76), +\$16,180,552 transfer from National Children's Study, and +\$6,307,000 transfer from NIH Office of AIDS Research, and \$33,000 lapse. Includes \$269,212,000 of AIDS funding.

(Continued from previous page)

Fiscal Years	Amount	Notes
2015	\$4,950,396,000	Prior to +\$2,632,000 transfer from NIH Office of AIDS Research and \$435,000 lapse. Includes \$269,660,000 of AIDS funding.
2016	\$5,214,701,000	Prior to -\$7,217,390 HHS Secretary's transfer, -\$1,192,000 transfer to NIH Office of AIDS Research, and \$122,000 lapse. Includes \$266,422,000 of AIDS funding.
2017	\$5,689,329,000	Prior to -\$11,971,000 HHS Secretary's transfer, -\$17,403,000 transfer to NIH Office of AIDS Research, and \$247,000 lapse. Includes \$249,019,000 of AIDS funding and \$300,000,000 of Cancer Moonshot SM funding.
2018	\$5,964,800,000	Prior to -\$13,309,000 HHS Secretary's transfer, -\$7,785,000 transfer to NIH Office of AIDS Research, and \$250,000 lapse. Includes \$241,234,000 of AIDS funding and \$300,000,000 of Cancer Moonshot SM funding.
2019	\$6,143,892,000	Prior to -\$19,730,000 HHS Secretary's transfer, -\$2,874,000 transfer to NIH Office of AIDS Research, and \$252,786 lapse. Includes \$241,979,000 of AIDS funding and \$400,000,000 of Cancer Moonshot SM funding.
2020	\$6,440,442,000	Prior to -\$4,000 transfer to NIH Office of AIDS Research, and \$254,618 lapse. Includes \$241,975,000 of AIDS funding and \$195,000,000 of Cancer Moonshot SM funding.
2021	\$6,559,852,000	Prior to -\$1,047,000 transfer to NIH Office of AIDS Research, Secretary's Transfer -\$19,109,000, and \$289,223 lapse. Includes \$240,513,000 of AIDS funding, and \$195,000,000 of Cancer Moonshot SM funding.
2022	\$6,912,522,000	Prior to -\$2,896,000 transfer to NIH Office of AIDS Research and \$248,297 lapse. Includes \$248,940,000 of AIDS funding, and \$194,000,000 of Cancer Moonshot SM funding.

(Continued from previous page)

Fiscal Years	Amount	Notes
2023	\$7,320,159,000	Prior to -\$2,918,000 transfer to NIH Office of AIDS Research, and \$234,418 lapse. Includes \$256,734,000 of AIDS funding, and \$216,000,000 of Cancer Moonshot SM funding.
1938 - 2022	\$167,178,409,220	

NCI Funding Trends

Funding amounts and percentages reflect actual obligations for each fiscal year.

NCI Funding

FUNDING BY MECHANISM, FY 2018–2023

(Dollars in Millions)

Mechanism	2018**	2019**	2020**	2021**	2022**	2023**
Total NCI	\$5,927.6	\$5,992.3	\$6,383.3	\$6,442.7	\$6,833.7	\$7,186.8
Research Project Grants	2,450.6	2,541.7	2,749.4	2,822.4	2,966.5	3,145.2
Cancer Centers	331.4	337.1	382.0	344.7	339.7	353.5
SPORes	115.8	110.7	113.2	119.6	128.2	124.1
Other P50s/ P20s	0.0	7.4	7.9	3.3	13.2	5.3
Specialized Centers	178.3	200.8	110.7	95.9	105.9	141.5
Clinical Cooperative Groups	255.3	290.1	295.6	300.0	307.9	303.6
R&D Contracts	825.4	768.1	823.0	812.2	835.8	899.1
Intramural Research	945.5	964.9	1,072.6	1,102.5	1,230.4	1,278.5
Other Mechanisms*	825.3	771.5	829.0	842.0	906.1	936.0

*Other mechanisms includes the Career Program, Cancer Education, Minority Biomedical Research Support, Other Research Grants, National Research Service Awards (NRSA), Research Management & Support, and Buildings & Facilities.

**Fiscal years 2023 through 2017 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2023 through 2018.

Percent Change by Mechanism

PERCENT CHANGE BY MECHANISM, FY 2018–2023

Mechanism	2017 to 2018**	2018 to 2019**	2019 to 2020**	2020 to 2021**	2021 to 2022**	2022 to 2023**
Total NCI	5.2%	1.1%	6.5%	0.9%	6.1%	5.2%
Research Project Grants	7.6%	3.7%	8.2%	2.7%	5.1%	6.0%
Cancer Centers	5.9%	1.7%	13.3%	-9.8%	-1.5%	4.1%
SPORes	3.9%	-4.4%	2.3%	5.6%	7.2%	-3.2%
Other P50s/ P20s	-100.0%	0.0%	6.5%	-58.4%	299.4%	-59.9%
Specialized Centers	31.5%	12.6%	-44.9%	-13.3%	10.4%	33.6%
Clinical Cooperative Groups	4.1%	13.6%	1.9%	1.5%	2.6%	-1.4%
R&D Contracts	-6.2%	-6.9%	7.1%	-1.3%	2.9%	7.6%
Intramural Research	5.1%	2.1%	11.2%	2.8%	11.6%	3.9%
Other Mechanisms*	7.0%	-6.5%	7.5%	1.6%	7.6%	3.3%

*Other mechanisms includes the Career Program, Cancer Education, Minority Biomedical Research Support, Other Research Grants, National Research Service Awards (NRSA), Research Management & Support, and Buildings & Facilities.

**Fiscal years 2023 through 2017 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2023 through 2018.

Percent Share of Total NCI Dollars

MECHANISM SHARE OF NCI BUDGET, FY 2018–2023


Mechanism	2018**	2019**	2020**	2021**	2022**	2023**
Research Project Grants	41.3%	42.4%	43.1%	43.8%	43.4%	43.8%
Cancer Centers	5.6%	5.6%	6.0%	5.4%	5.0%	4.9%
SPOREs	2.0%	1.8%	1.8%	1.9%	1.9%	1.7%
Other P50s/ P20s	0.0%	0.1%	0.1%	0.1%	0.2%	0.1%
Specialized Centers	3.0%	3.4%	1.7%	1.5%	1.6%	2.0%
Clinical Cooperative Groups	4.3%	4.8%	4.6%	4.7%	4.5%	4.2%
R&D Contracts	13.9%	12.8%	12.9%	12.6%	12.2%	12.5%
Intramural Research	16.0%	16.1%	16.8%	17.1%	18.0%	17.8%
Other Mechanisms*	13.9%	12.9%	13.0%	13.1%	13.3%	13.0%

*Other mechanisms includes the Career Program, Cancer Education, Minority Biomedical Research Support, Other Research Grants, National Research Service Awards (NRSA), Research Management & Support, and Buildings & Facilities.

**Fiscal years 2023 through 2017 includes Cancer Moonshot funding appropriated that fiscal year and excludes all carryover obligations for fiscal years 2023 through 2018.

Extramural vs Intramural and RMS Funding

The following is a comparison broken out by mechanism and total between extramural dollars spent versus Intramural Research Program (IRP) and Research Management and Support (RMS).



*Fiscal years 2023 through 2017 include Cancer Moonshot funding appropriated that fiscal year and exclude all carryover obligations for fiscal years 2023 through 2018.

FY 2017–2023 TOTAL NCI FUNDING

(Dollars in Millions)

2017*	2018*	2019*	2020*	2021*	2022*	2023*	2017-2023 % Change
\$5,636.4	\$5,927.7	\$5,992.3	\$6,383.4	\$6,442.7	\$6,833.7	\$7,186.8	5.2%

*Fiscal years 2023 through 2017 include Cancer Moonshot funding appropriated that fiscal year and exclude all carryover obligations for fiscal years 2023 through 2018.

FY 2017–2023 EXTRAMURAL FUNDING

(Dollars in Millions)

Mechanism	2017*	2018*	2019*	2020*	2021*	2022*	2023*	2017- 2023 % Change
Research Project Grants	\$2,278.4	\$2,450.6	\$2,541.7	\$2,749.4	\$2,822.4	\$2,966.5	\$3,145.2	6.0%
Cancer Centers	313.0	331.4	337.1	382.0	344.7	339.7	353.5	4.1%
SPORes	111.4	115.8	110.7	113.2	119.6	128.2	124.1	-3.2%
Other P50s/ P20s	1.3	0.0	7.4	7.9	3.3	13.2	5.3	-59.8%
Other Specialized Centers	135.6	178.3	200.8	110.7	95.9	106.0	141.5	33.5%
Other Research Grants	481.9	537.9	506.8	548.1	556.1	624.8	621.5	-0.5%
NRSA	77.6	82.4	87.0	96.4	93.0	91.1	90.3	-0.9%
R&D Contract	880.4	825.4	768.1	823.0	812.2	835.8	899.1	7.6%
Buildings & Facilities	30.0	18.0	18.0	30.0	30.0	30.0	30.0	0.0%
Total Extramural Funds	\$4,309.7	\$4,539.8	\$4,577.5	\$4,860.7	\$4,877.3	5,135.3	\$5,410.5	5.4%

*Fiscal years 2023 through 2017 include Cancer Moonshot funding appropriated that fiscal year and exclude all carryover obligations for fiscal years 2023 through 2018.

FY 2017–2023 INTRAMURAL AND RMS FUNDING

(Dollars in Millions)

Mechanism	2017*	2018*	2019*	2020*	2021*	2022*	2023*	2017- 2023 % Change
Intramural Research	\$899.7	\$945.5	\$964.9	\$1,072.6	\$1,102.5	\$1,230.4	\$1,278.5	3.9%
RMS	427.0	442.4	449.9	450.0	462.9	468.0	497.8	6.4%
Total IRP & RMS Funds	\$1,326.7	\$1,387.9	\$1,414.8	\$1,522.6	\$1,565.4	\$1,698.4	\$1,776.3	4.6%


*Fiscal years 2023 through 2017 include Cancer Moonshot funding appropriated that fiscal year and exclude all carryover obligations for fiscal years 2023 through 2018.

Comparison of Dollars, Positions, and Space

This page presents tables comparing NCI's budget, full-time equivalent (FTE) positions, and occupied space from fiscal years 2014 through 2023.

NCI's budget is displayed in millions of dollars and includes the Cancer MoonshotSM funding in fiscal years 2017 through 2023. FTEs are the number of work years for appointed employees of NCI. A work year equals 2,080 hours. Space is in thousands of square feet, excluding NCI's Frederick National Laboratory for Cancer Research.

In fiscal year 2020, NCI acquired new laboratory space called the Consolidated Research Lab in Shady Grove and new administrative space in Bethesda.



NCI Personnel

The table below displays NCI staffing levels, by type of appointment, for fiscal years 2010 through 2023.

- full-time equivalents represent 2,080 hours per person employed
- full-time and part-time appointments include employees from NIH Employment Report 71E
- training Fellows including visiting fellows, Cancer Research Training Award (CRTA) and the few remaining Intramural Research Training Award (IRTA), biotech, and tech transfers
- total employees include full-time and part-time permanent tours


NCI PERSONNEL, FY 2010–2023

Fiscal Year	Full Time Permanent	Other Than Full Time Permanent	Training Fellows	Total Personnel Resources
2010	2,148	1,011	1,073	4,232
2011	2,180	1,029	1,108	4,317
2012	2,139	997	906	4,042
2013	2,173	948	847	3,968
2014	2,139	923	879	3,941
2015	2,119	897	947	3,963
2016	2,050	1,001	972	4,023
2017	2,156	890	1,042	4,088
2018	2,083	845	1,045	3,973
2019	2,101	879	1,061	4,041
2020	2,136	952	1,150	4,143
2021	2,188	1,007	1,133	4,328
2022	2,187	1,047	1,153	4,387
2023	2,266	1,050	1,186	4,502

NCI and NIH AIDS Funding History

NCI has played a major role in HIV/AIDS research since the beginning of the AIDS epidemic. Scientists within and supported by NCI have made a number of key discoveries. HIV/AIDS research is conducted throughout the divisions and offices of NCI and is coordinated by the [NCI Office of HIV and AIDS Malignancy](#).

In addition, because HIV/AIDS transcends every area of clinical medicine and basic scientific investigation, the NIH AIDS research effort involves every NIH Institute and Center. The NIH Office of AIDS Research has primary responsibility for planning and coordinating AIDS research across NIH.



Cancer MoonshotSM – Recent Fiscal Year Funding

The 21st Century Cures Act, which was signed into law in December 2016, authorized \$1.8 billion to fund the Cancer Moonshot over a 7-year period. The goal of the Cancer Moonshot is to accelerate progress in cancer, including prevention and screening, from cutting edge basic research to wider uptake of standard of care.

The following pages contain information on the \$216 million of Cancer Moonshot funding received during fiscal year 2023.

More information on Cancer Moonshot can be found by visiting the [NCI Cancer Moonshot initiative page](#).

Information on recent funding opportunity announcements can be found on the [Cancer Moonshot Funding Opportunities page](#).

CANCER MOONSHOT FISCAL YEAR SUMMARY

(Whole Dollars)

Fiscal Year	Authorization
2017	\$300,000,000
2018	\$300,000,000
2019	\$400,000,000
2020	\$195,000,000
2021	\$195,000,000
2022	\$194,000,000
2023	\$216,000,000
Total	\$1,800,000,000


Funding for the Cancer Moonshot is appropriated on an annual basis. The following pages contain information on the \$216 million of Cancer Moonshot funding received during fiscal year 2023.

Cancer MoonshotSM – Obligations by Budget Mechanism

With over \$124 million obligated for Cancer Moonshot activities in fiscal year 2023, funding was allocated into four budget mechanisms: research grants, research and development (R&D) contracts, intramural research, and research management and support, as shown in the chart below.

FY 2023 Cancer Moonshot and Carryover – Obligations by Mechanism

Fiscal Year 2023



Includes new obligations and recoveries from fiscal years 2017, 2018, 2019, 2020, 2021 and 2022 carryover accounts.

FISCAL YEAR 2023 CANCER MOONSHOT AND CARRYOVER: OBLIGATIONS BY MECHANISM

(Whole Dollars)

Type of Mechanism	Mechanism	Number	Amount*
Research Project Grants (RPGs)	Competing	17	\$10,107,821
	Noncompeting	27	\$23,509,144
	Administrative Supplements	0	\$4,429,604
	Subtotal, without SBIR	39	\$38,046,569
	SBIR/STTR Grants	2	\$947,801
	Subtotal, RPGs	46	\$38,994,370
Centers	Cancer Centers Grants-P30s	0	\$3,269,673
	P50s	11	\$11,971,432
	Cooperative Agreements-U54s/U41s	10	\$7,502,754
	Subtotal, Centers	21	\$22,743,859
Other Research	Resource Grants-U24s/U2Cs	13	\$29,363,630
	Subtotal, Other Research	13	\$29,363,630
Subtotal, Research Grants		84	\$91,101,859
Intramural Research	IR Program	0	\$7,086,652
Research Management & Support	RMS	0	\$236,744

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount*
R&D Contracts	R&D Contracts	14	\$19,241,154
	SBIR/STTR Contracts	3	\$6,739,920
	Subtotal, R&D Contracts	17	\$25,981,074
Total			\$124,406,329

* Includes new obligations and recoveries from fiscal years 2017, 2018, 2019, 2020, and 2021 carryover accounts.

Cancer MoonshotSM – Funding by Research Category

To ensure the Cancer Moonshot goals and approaches were grounded in the best science, NCI convened a [Blue Ribbon Panel of scientific experts](#) as a working group to the National Cancer Advisory Board. In September of 2016, the Blue Ribbon Panel presented a [final report](#) outlining 10 research recommendations that represent areas that are well-positioned to accelerate progress in cancer prevention, diagnosis, treatment, and care.

The following research categories align with these 10 recommendations:

CANCER MOONSHOT BY CATEGORY, FY 2023

(Whole Dollars)

Research Category	Amount*
Network for Direct Patient Engagement	\$16,733,788
Cancer Immunotherapy Translational Science Network	\$20,418,132
Therapeutic Target Identification to Overcome Drug Resistance	\$10,507,238
A National Cancer Data Ecosystem for Sharing and Analysis	\$850,000
Fusion Oncoproteins in Childhood Cancers	\$1,222,115
Minimize Cancer Treatment's Debilitating Side Effects	\$6,699,835
Prevention and Early Detection: Implementation of Evidence-Based Approaches	\$24,170,151
Retrospective Analysis of Biospecimens from Patients Treated with Standard of Care	\$0
Generation of Human Tumor Atlases	\$10,669,149
Development of New Enabling Cancer Technologies	\$16,121,154
Other Cancer Moonshot Priority Activities (e.g., Partnership for Accelerating Cancer Therapies)	\$17,014,767
Total	\$124,406,32

* Includes new obligations and recoveries from fiscal years 2017, 2018, 2019, 2020, 2021, and 2022 carryover accounts.

This data was published on June 20, 2024, using budget data finalized on December 29, 2022, for fiscal year 2023.



**NATIONAL
CANCER
INSTITUTE**

cancer.gov